Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Franco-Nevada Corporation (FNV) vs Revvity Inc (RVTY) Price & Performance

Franco-Nevada CorporationTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Franco-Nevada Corporation vs Revvity Inc — how do they compare? Franco-Nevada Corporation trades at $233.84 (market cap $46.80B), while Revvity Inc trades at $151.84 (market cap $17.30B). The key difference: Franco-Nevada Corporation is far larger — about 2.7× Revvity Inc's market cap, and Franco-Nevada Corporation pays the higher dividend (0.72%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Revvity Inc for 13 Days on average.

FNVRVTY
Market Cap
$46.80B$17.30B
Volume
310,6921,387,588
Sector
Basic MaterialsHealth
52-Week High
$280.82$157.36
52-Week Low
$183.97$82.26
Typical Hold Time
0 Days13 Days
Enterprise Value
$45.79B$19.62B
Dividend Yield
0.72%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Franco-Nevada Corporation

Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.

The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.

Revvity Inc

RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.

RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNV
100% Buy0% Sell
Avg holding period · 0 Days
RVTY

No sentiment data available yet.

About Franco-Nevada Corporation

Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).

Read more on FNV →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →